P3H4 (Gene)

Organism:

Homo sapiens

Gene:

TARGET ID 04096

Synonyms:ENTREZ:10609, HGNC:16946, LEPREL4, MIM:617419, NM_006455, NO55, NOL55, NP_006446, P3H4, SC65, XM_006721640, XM_024450538, XP_006721703, XP_024306306, prolyl 3-hydroxylase family member 4 (inactive)

Omim:OMIM:617419

Id:ENSG00000141696

Hgnc:HGNC:16946

Entrez:10609

Ensembl:ENSG00000141696

Description:prolyl 3-hydroxylase family member 4 (inactive)

This nucleolar protein was first characterized because it was an autoantigen in cases on interstitial cystitis. The protein, with a predicted molecular weight of 50 kDa, appears to be localized in the particulate compartment of the interphase nucleolus, with a distribution distinct from that of nucleolar protein B23. During mitosis it is associated with chromosomes. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View P3H4's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with P3H4.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using P3H4.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for P3H4.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with P3H4.

Results found

Linked to

	Label	Description
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE102467 3 V 2 PAZOPANIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142210 11 V 10 PANOBINOSTAT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 4 PALMITIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE102467 3 V 2 PAZOPANIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE142210 11 V 10 PANOBINOSTAT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 4 PALMITIC ACID HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 10 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.